MINNEAPOLIS, Sept. 28 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq:
UPI), a medical device company that develops, manufactures and
markets innovative proprietary products to treat voiding
dysfunctions, today announced that CIGNA Government Services,
Palmetto GBA for Ohio and
West Virginia, and Pinnacle
Business Solutions, Inc., all regional Medicare carriers, now cover
posterior tibial nerve stimulation (PTNS) using the Urgent® PC
Neuromodulation System for the treatment of the symptoms of
overactive bladder. CIGNA Government Services currently
administers benefits for Medicare beneficiaries in Idaho and North
Carolina. The Palmetto GBA coverage extends to
Medicare beneficiaries of Ohio and
West Virginia, in addition to
previously announced coverage in South
Carolina. Pinnacle Business Solutions, Inc. currently
covers Medicare beneficiaries in Arkansas and Louisiana.
All three regional Medicare carriers will cover PTNS therapy for
patients who have failed, or demonstrated intolerance to, standard
anticholinergic drug therapy. Coverage by CIGNA Government
Services and Palmetto GBA, Ohio
and West Virginia includes an
initial course of 12 weekly PTNS treatments, and, for those
patients who respond to the initial treatments, additional
treatments once every three weeks for up to one year.
Coverage by Pinnacle Business Solutions, Inc. includes a
course of 12 weekly treatments. Claims for PTNS treatments
can be submitted electronically using the unlisted CPT® code 64999.
In addition, CIGNA Government Services will reimburse, when
medical necessity is met, up to three physician consultations to
evaluate and manage treatments during the initial course of PTNS
therapy.
These carriers are in addition to the coverage initiated by
Noridian Administrative Services, LLC and Palmetto GBA,
South Carolina, two regional
Medicare carriers that the Company announced in August.
Noridian administers benefits for Medicare beneficiaries in
North and South Dakota,
Montana, Wyoming, Utah
and Arizona. As previously
mentioned, the Palmetto GBA policy covers Medicare beneficiaries in
South Carolina.
"It is very encouraging that coverage of PTNS treatments using
our Urgent PC Neuromodulation System has been expanded to include
three additional regional Medicare carriers," said David Kaysen, President and CEO of Uroplasty,
Inc. "This success reflects the effort by our field based
reimbursement managers working with the medical directors of these
carriers. These regional Medicare carriers, as part of their
analysis of PTNS, reviewed our strong clinical data and determined
that PTNS treatments should be considered medically necessary for
the beneficiaries within their coverage areas. We continue to
meet with medical directors of other Medicare carriers and private
payers to present our strong clinical data and encourage them to
cover and reimburse PTNS treatments."
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned
subsidiaries in The Netherlands
and the United Kingdom, is a
medical device company that develops, manufactures and markets
innovative proprietary products for the treatment of voiding
dysfunctions. Our focus is the continued commercialization of our
Urgent PC system, which we believe is the only FDA-approved
minimally invasive nerve stimulation device designed for
office-based treatment of urinary urgency, urinary frequency and
urge incontinence – symptoms often associated with overactive
bladder.
We also offer Macroplastique Implants, an injectable urethral
bulking agent for the treatment of adult female stress urinary
incontinence primarily due to intrinsic sphincter deficiency. For
more information on the company and its products, please visit
Uroplasty, Inc. at www.uroplasty.com.
Forward-Looking Information
This press release contains forward-looking statements that
reflect our best estimates regarding future events and financial
performance. These forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ
materially from our anticipated results. We discuss in detail
the factors that may affect the achievement of our forward-looking
statements in our Annual Report on Form 10'K filed with the SEC.
In particular, we cannot be certain that the rate of
reimbursement for PTNS treatments will be adequate to justify the
cost of our product, that other Medicare carriers or private payers
will provide coverage for this treatment, or that any of the other
risks identified in our 10-K will not adversely affect our
expectations as described in these forward-looking statements.
For Further
Information:
|
|
|
Uroplasty, Inc.
|
EVC Group
|
|
David Kaysen, President and CEO,
or
|
Doug Sherk/Jenifer Kirtland
(Investors),
|
|
Medi Jiwani, Vice President,
CFO, Treasurer
|
415.896.6820
|
|
952.426.6140
|
Chris Gale (Media),
646.201.5431
|
|
|
|
SOURCE Uroplasty, Inc.
Copyright . 28 PR Newswire